CME Group Q2 2023 Earnings Call Transcript

Presentation

[Operator]

Greetings and welcome to the CME Group Second Quarter 2023 Earnings Conference Call. [Operator Instructions]

It's my pleasure to turn the conference over to Adam Minick. Please go ahead.

[Adam Minick, Senior Director, Investor Relations at CME Group]

Good morning. I hope you're all doing well today. We will be discussing CME Group's second quarter 2023 financial results. I'll start with the Safe Harbor language, then I'll turn it over to Terry.

Statements made on this call and in the other reference documents on our website that are not historical facts are forward-looking statements. These statements are not guarantees of future performance. They involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or implied in any statements. Detailed information about factors that may affect our performance can be found in the filings with the SEC, which are on our website.

Lastly, on the final page of the earnings release, you will see a reconciliation between GAAP and non-GAAP measures.

With that, I'll turn the call over to Terry.

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

Thank you, Adam; and thank you all for joining us this morning. As Adam said, we released our executive commentary earlier today, which provides details on the second quarter of 2023. I will make a few brief comments on the quarter and current outlook, and Lynne will summarize our financial results. In addition to Lynne, we have other members of our management team present to answer questions after the prepared remarks.

As we mentioned last quarter, 2023 is setting up to be an extremely favorable backdrop for risk management. The continued geopolitical uncertainty, and the increasing cost of capital for businesses, are just a couple of the things that have helped us deliver our financial results for the quarter. The benefit of CME Group's diverse product portfolio, spanning six asset classes was on display. ADV across our Commodities asset classes increased 20%, with 34% growth in Agricultural products, 27% growth in Metals and 9% in Energy. Interest rates, average daily volume of 11.3 million was up 6% for the quarter and is up 11% compared with the first half of 2022.

Despite a substantial decline in equity market volatility, our Equity class delivered average daily volume of 6.2 million contracts during Q2. Our non-US ADV was 6.3 million contracts for the quarter, including double-digit year-over-year growth in Ags, Metals and Energy. Options, again, played a critical role in Q2, with ADV growth of 20% to 4.7 million contracts including the highest quarterly Agricultural options ADV on record, up 32% from Q2 last year. Our product innovation in this area has driven strong growth with new participants and more product choice to more precisely match risk, as clients continue to look for ways to protect their portfolios in these uncertain times.

As it relates to our rates market, expectations of short-term rate changes up or down, and a divergent economic data, continue to drive risk management. As we saw with the recent resolution of the debt ceiling, the Treasury bill issuance increased dramatically. Over time, we expect that more coupon issuance and ongoing debt financing will contribute to greater hedging needs for years to come.

On the Commodities side, exports are increasing the demand for risk management using our benchmark agriculture and energy products. With this favorable backdrop, we will continue to focus on opportunities to accelerate growth, including our recent announcement with DTCC to increase cross-margining opportunities for the Treasury markets. Additionally, our ongoing focus on product innovation and data services continues to enhance trading opportunities for our clients. We believe the strong underlying environment combined with our strategic execution across growth initiatives positions us for accelerated growth in coming years.

With that, I'll turn the call over to Lynne for the second quarter financial results.

[Lynne Fitzpatrick, Chief Financial Officer at CME Group]

Thanks, Terry. During the quarter, CME Group generated $1.4 billion in revenue, up about 10% compared with a strong second quarter last year. Clearing and transaction fees grew over 9%, while market data revenue increased 8% versus Q2 2022.

Expenses on an adjusted basis were $452 million for the quarter and flat versus the first quarter at $374 million, excluding license fees. This quarter, our investment in our cloud migration was approximately $15 million. Our adjusted operating margin for the quarter expanded to 66.8%, up over 250 basis points compared to the same period last year.

CME Group had an adjusted effective tax rate of 23.3%, which resulted in adjusted net income of $836 million, driving diluted earnings per share of $2.30, both up 17% from the second quarter last year. In addition to our expanding margins, the strength of our operating model was evident this quarter as we delivered an increase of approximately $120 million in both revenue and adjusted net income compared to last year.

Capital expenditures were approximately $22 million and CME Group paid dividends during the quarter of $400 million. Our ending cash balance was approximately $2 billion.

As you can see with the current results, the entire team at CME Group is focused on growing the business. We have delivered double-digit adjusted earnings growth in each of the last eight quarters. Although it is challenging to predict volumes or market conditions over the short-term, wen you look at the last five, seven or 10-year period, we have grown our earnings by a compound annual growth rate of 10% to 12% per year despite multiple periods of zero interest rate policy and the impacts of the pandemic on the global economy.

As Terry mentioned, we are in a favorable environment for risk management and we're taking a number of actions designed to accelerate our growth going forward through customer expansion, new product and service innovation and enhancing capital efficiencies. Given this, our goal as a management team is to deliver growth in the coming decade above these historical averages.

Terry, I'll turn the call back to you.

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

Thank you, Lynne. We are very pleased with the continued strong financial performance of the Company.

Before I open the call for questions I'd like to ask Tim McCourt and Derek Sammann to comment briefly on the recent trends that we are seeing in short-dated options products. And I'll go to Tim first. Tim?

[Tim McCourt, Senior Managing Director, Global Head of Financial and OTC Products at CME Group]

Thanks, Terry. We are pleased with the performance of our equity options on futures, which year-to-date drove 1.3 million contracts per day. Short-dated options, including zero days to expiry or zero DTE options remain a strong driver of our multi-year growth. Volume in our same day expiring options is up 33% from last year and up 220% since 2021, and now make up 27% of our equity options volume.

It is important to also note, we are seeing volume and open interest growing across the entire maturity curve. Year-to-date equity options are up 6% compared to a record year in 2022 with particular strength in Nasdaq options and Russell 2000 options which are both up double-digits. This strong growth story further demonstrates the value customers continue to derive from trading products on the most important equity indices at CME Group. And while short-dated options have been largely an equities story to-date, we're beginning to see expansion to other parts of the portfolio, which Derek will speak to now.

[Derek Sammann, Senior Managing Director, Global Head of Commodities, Options & International Markets at CME Group]

Thank you, Tim. As we've discussed in recent quarters, options have become a larger part of our global customers' risk management and trading strategies. Year-to-date, average daily volume in our Options franchise across all asset classes is up 26% driven by Interest Rates, Metals and Equities, and our non-US options business is up 33% through June. Within this larger growth story, we have seen growing demand for weekly options expirations across all asset classes, with weekly options volume up 21% year-to-date and growing to 26% of total options trading.

In addition to equities, commodities traders have similarly embraced shorter-dated expirations, which allow our global customers to hedge specific event risks, such as crop reports and OPEC meetings. Agricultural weekly options were up 168% in the second quarter, which contributed to a record quarter for agricultural products overall. In Energy, our WTI weekly options grew 126% versus second quarter last year, while our gold weekly options were up 33% year-over-year. The strength of our Options franchise allows CME Group to uniquely deliver significant capital and operational efficiencies and meets our customers' need for short-dated options to help them most effectively manage risk across their entire portfolio.

And with that, we can now open the call for questions.

Questions and Answers

[Operator]

Thank you. [Operator Instructions] Our first question comes from the line of Benjamin Budish with Barclays. Please go ahead, sir.

[Benjamin Budish, Analyst at Barclays]

Hi there. Thanks so much for taking the question. I wanted to go back to a comment that you made, Lynne, in your prepared remarks just about sort of positioning the business to kind of grow faster than the historical average over the next decade. If you could maybe unpack that a little bit, what are sort of like the key elements that you see, is it sort of a global increase in just need to manage risk, is it more customers, is it sort of increasing RPC, more volatility? How do you kind of think about what that looks like over the next decade as you indicated?

[Lynne Fitzpatrick, Chief Financial Officer at CME Group]

Sure, I'll start and a number of my colleagues will want to jump in here. I think the growth story is one that we've been talking about for a while, a number of the levers that we look at is that new customer expansion, is that international growth, new product innovation has been certainly a big focus, looking at the OTC alternative products, as well as looking at capital efficiencies.

So, I don't know, Julie, if you want to comment on a few of those initiatives that are underway.

[Julie Holzrichter, Chief Operating Officer at CME Group]

Yeah. I mean, the -- certainly the cross-margin initiative is one that our clients are quite excited about and one that we have talked about for a number of years delivering that is going to be an important thing. Capital efficiencies continues to be at the top of their list and a very important thing in order to deploy more capital and do more trading at CME Group.

I think the macroeconomic environment is quite positive across a number of our asset classes. And feedback from our clients is that they are using our market to hedge those growing risks, as well as a need -- and seen that the increased Treasury issuance on the horizon that's going to mean more hedging from broker-dealers as well.

Buy-side, again, I think across the segments, we're sensing quite a bit of positivity. And as we continue to roll out more products, the options that Derek and Tim talked about earlier also is another highlight that we're giving our clients a lot of different instruments to be able to express, therefore the expectations about the marketplace and we feel we're very well-positioned from our team being able to support them globally. And that is certainly part of the international growth that we have commented on, and believe it still suits us quite well for the future.

We also feel real good about our data services business delivering the 8% growth and the number of new products, services, and analytics that the team is working hard to deliver, in some cases, things that we had not previously rolled out to our customer based on our data. So, all of those things give us a positive outlook for the future.

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

Thanks, Julie; and thanks, Lynne. Ben, hopefully, that gave you some color on what we're thinking to exchange.

[Benjamin Budish, Analyst at Barclays]

Yeah. Very helpful. Thanks, guys.

[Operator]

Thank you. Our next question comes from the line of Dan Fannon with Jefferies. Please proceed with your question.

[Dan Fannon, Analyst at Jefferies & Company]

Thanks. Good morning. I guess a little bit of a follow-up on that. Just you've had good volumes in the first half of the year, but the investor comments and concerns continues around -- continues to be about sustainability of that and potentially the worst or I'm sorry, the best being behind you. So as you think about kind of all the growth opportunities you see and you highlighted already, maybe pick the one or two that you could -- that you would highlight here in the short-term. And then maybe expand a bit upon the DTCC partnership and what we should think about in terms of how that gets rolled out and maybe the timing and the potential implications of that agreement.

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

So, Dan, thank you for your question. You got a couple of questions in there. So the DTCC, we did put out the release with the DTCC just a couple of weeks back, and we're hoping -- we're waiting on regulatory approval, which we are expecting and hopefully, we will have that implemented going into the first quarter of 2024. We feel fairly confident about that now. So, otherwise, we wouldn't have put out the release. So, we are looking at that. And again, I think you recall going back many quarters, a couple of years back when Sean Tully gave you some figures about what he expected as far as the efficiencies, what that agreement could mean once we acquired NEX, which we thought we'd be somewhere today around 20% and we thought that we could be 70%-plus, we still feel very confident that that is going to be the case once this gets fully implemented and put forward. So, that's the DTCC question.

The other question was on a couple of drivers for the business, I think is what you asked on the out years. And I'll ask Tim to make a couple of comments as it relates to his business and Derek as well.

[Tim McCourt, Senior Managing Director, Global Head of Financial and OTC Products at CME Group]

Sure. Thanks, Terry. As Terry mentioned in the opening remarks, there's certainly continued period of uncertainty in front of us, which will provide a continued tailwind for CME as we continue to offer risk management solutions for our clients. I think drilling down a little bit, if we think about some of the various asset classes, if we look at the rates complex, where we successfully completed the transition from LIBOR to SOFR, that's not the end of the journey, but it's really the beginning of what's in front of us.

To Julie's comments, if you think about coupling that with the macroeconomic backdrop on a tightening and the resolution of the debt ceiling, we're only in the early days of seeing some of those drivers factor into their risk management needs of our client. And what I mean by that is, if we look at the recent Treasury issuance, most of the analysts were expecting $1.2 trillion to be issued through now -- through June and year-end. Most of that issuance is going to T-Bills at present, instead of coupons.

If we look at the product offering of CME at present, that is not something that we currently offer with respect to the risk management or accessing the T-Bills market. So as that issuance moves from T-Bills to coupons, that will be buttressing our Treasury complex both within our futures and options, as well as BrokerTec. I think then when you also look at the uncertainty in the rates marketing, with the FOMC meeting today, there is over 99% chance of another 25 basis point increase. But if you look further out, they are expected to be somewhat range-bound for the rest of the year with possibly one more 25 basis point increase in 2023, but then you're seeing the Fed watchful and CME predict a 51% chance of a reduction before March of 2024. So, sort of this consensus view that rates could go up, stay the same or go down is going to be a tremendous backdrop for our clients that need to manage that uncertainty and have all the product to do so at CME across the various asset classes, across futures, options, swaps and the cash market.

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

So, let me make a couple of comments too, Dan, because I think it's an important question that you asked. And it's really tough for us to predict the future. But, as you recall at the beginning of 2022, I said it was going to be a very exciting year, because a lot of things are setting up in favor of risk management. We think this is exactly the environment that we've been talking about for several years that we see going out for several more to come.

So, that's why we're really excited about some of these out-years, some of the things that Tim just referenced, risk management cannot be neglected for one moment for any business. We have multiple examples of failure, whether it's in small bank failures and others that continued to not manage risk, they're going to be, we think, potentially have to manage their risk that if they're going to stay in business, there's a whole host of factors that are coming to fruition that we think are of tailwind for CME Group.

I'm going to let Derek to make a few comments on his asset classes, because I think this is an important question not only that you're asking, but for all the analysts and investors that listen to. Derek?

[Derek Sammann, Senior Managing Director, Global Head of Commodities, Options & International Markets at CME Group]

Yeah. I think that you've already heard from Terry on the options and commodities. Just a couple of data points that I think underscore the breadth and the scale of the options growth. Not only is our non-US options growing faster than our US options, options are growing faster than the franchise overall. But also, if you look at the first-half year volumes, every single asset class with our client segment with the exception of banks is up -- this business is up 24% year-to-date. And what's most important is our buy-side client volume and options is up 38% year-to-date. So, it speaks to the breadth and the scale and I think the attractiveness of our options solutions across the entire customer range. So, this is not led by one asset class, not led by one client segment. So, it's really grown in scale across a lot of client segments.

And then on the commodities side, you heard Terry talk a lot about the benchmark status of our products. We have built long and hard into expanding our portfolio of products. If you look at what we've done in our Energy franchise, building up the crudes grades contracts to both defend, but also expand the success and the validity of our WTI market with that crudes grades contracts, we set an all-time record of open interest in over 500,000 contracts, open interest in those products. So, as the world evolves, this has been a multi-year story of expansion of our benchmarks, serving our clients as the world globalized and in some cases the world fragments, we have products for each of those scenarios. So, that's what we do. We solve client need, and we fill in parts of their portfolio that they need risk management and we become their solution provider.

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

And as we said, Dan, we can't predict volumes, but as I've said in my prepared remarks earlier, when you're looking at the largest asset class in the US equity markets and the equity markets around the world and basically a zero vol environment right now and we still trade at 6.2 million contracts a day. I think that goes to show you what can happen even when there is no vol and people say, where are the future volumes at, I think we're just kind of given you an example, where we see they are at even in low-vol situation.

[Dan Fannon, Analyst at Jefferies & Company]

Great. That's helpful. Thank you very much.

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

Thanks, Dan.

[Operator]

Thank you. Coming up next we have a question from the line of Kyle Voigt with KBW. Please proceed with your question.

[Kyle Voigt, Analyst at Keefe, Bruyette & Woods]

Hi. Good morning. Maybe a question for Terry. I mean, since early last year you sounded more open to executing on M&A if the right opportunity presented itself. Given M&A announcements or seeing from some of your peers domestically and internationally, can you just provide an update on the M&A environment? And given that you've not executed or announced any deals, are you not seeing the right opportunities in terms of checking the right boxes or has that been more price-driven?

And then also, maybe a question for Lynne or to you, Terry, do you think in terms of the next 10 years, as you mentioned kind of accelerating the growth, should we think about M&A as being a larger driver of accelerating that growth over the next 10 years versus what we saw over the last 10 years?

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

Kyle, it's a great question. I think when you're looking out several years into future, there's a lot of things that can happen. And one of the things that I see happening, shape CME in the future is the technology growth that we have with our Google transaction that will allow us to do certain things and maybe our competitors can't or we don't need to do M&A in order to accomplish those goals of growth going forward. So, I think, we're in a very strong position from that standpoint.

As far as M&A and what my competitors are doing, I don't like to comment on what they're doing. I'm not in the room thinking, talking to them about what strategic analysis they did, why they're doing those type of transactions. As I've said, we will only do things that we think are strategically benefit to our investors and to our clients. And again, right now we are focused on the growth of this Company through many different avenues. And if in fact there was a transaction, I am still open to it, but it's not going to be out from left field, I assure you. That's something that we've been very focused on and I'm not saying my competitors are, they're just doing different things.

So, we have a strong franchise, we're going to continue to build on it. Tim made reference to early innings in risk management and some of these products. We truly believe that in the distribution of our products, the technology that -- and the market data that Julie is working on, what we're doing with Google we think is really exciting going forward. So, we don't necessarily need to do M&A, but we're not going to shy away from it, if in fact, we see it's a benefit to our investors.

And, Lynne, if you want to comment further.

[Lynne Fitzpatrick, Chief Financial Officer at CME Group]

Yeah, I think Terry covered it well. We're looking at the organic growth and if there were opportunities out there, it's certainly something we look at, but we've been very disciplined in our approach to M&A as you've seen over the years.

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

And, Kyle, I will make one more reference and I think I've said this on a prior call. We are in a very strong capital position, if in fact there was an M&A transaction to come our way, where some of our so-called peers, as you referenced, they are getting heavily levered right now and when assets get shopped, they're going to get shopped to people that can afford to pay for them, no matter what they are. It doesn't mean that we're going to acquire them, but we're in a strong position to look at a lot of things strategically that may or may not benefit our business and we will make the decisions based on that.

[Kyle Voigt, Analyst at Keefe, Bruyette & Woods]

Understood. Thank you.

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

Thank you.

[Operator]

Thank you. Our next question comes from the line of Simon Clinch with Atlantic Equities. Please proceed with your question.

[Simon Clinch, Analyst at Atlantic Equities]

Hi, everyone. Thanks for taking my question. If we could just run -- go back to what, Lynne, what you were talking about in terms of the, I guess, the expanding product opportunities and the pipeline for market data, or maybe it was Julie who was talking about this. But could you expand on, sort of, I guess, how influence that has been or accelerated that has been by the Google partnership or if that has yet to come and perhaps give us a flavor of that, I guess, the pace of innovation over the next several years.

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

Sunil or Julie, you want to touch on that between the market data, then the Google partnership?

[Sunil Cutinho, Chief Information Officer at CME Group]

I'll kick off Terry, and then I'll have Julie speak to the commercial side. In terms of data platform, we have finally built it and it's available with about 24 petabytes of data. We have developed a set of services that we are working on releasing to our clients. I will let Julie speak a little bit about the commercial opportunity in that area.

[Julie Holzrichter, Chief Operating Officer at CME Group]

Yes, Simon, why don't I just start for a minute just talking about the data services performance and then just quickly go into some of the product buildout that we've been working on with Google. As I mentioned earlier, this quarter we were up 8% versus where we were a year ago. And that is driven from high demand from our professional user base, as well as our retail clients. And we're seeing a steady increase in the number of those professional traders that are accessing our real-time exchange content, and really seeing growth across all of those subscriber segments out there.

In Q2, we did not see as many of those one-time true-ups as we saw in the first quarter. So, we definitely still had positive growth. But if you remember back to Q1, Lynne had mentioned some of those one-time payments. So, those can come from everything from audits, true-ups, and derived data, audit fees, even true-ups to real-time subscribers from accruals. So just wanted to call that out as well. We've continued to say those are sporadic revenue items, but it's worth calling that out this quarter.

And again, we're feeling quite positive about where the device usage is, as well as the new products that we've been able to introduce. As Sunil pointed out, for us being able to really get our data into Google Cloud at a magnitude that we're sitting at now has allowed us to accelerate the development of new products for our data business and including new analytics products as well. So, we've been highly focused on how we're going to enhance the business and then manage through making our data more available through APIs, increasing the flexibility in how we can package our data, how we distribute our data, how we're going to be able to price our data. All of this is just much better enabled once this is assessable through the cloud, as well as we believe, making it much more easy for clients that don't access CME data today to be able to use these new services.

The computation that you can do is just far enhanced from what we're doing in an on-prem environment. And so, that's allowing us to create as well some new compelling trade execution analytics. We've been able to put that into production this quarter and we'll be sharing that with our clients shortly. And so, this is really us being able to leverage our own proprietary data and giving our clients this benchmarking activity and allowing them to really take action on that data and providing them with insights.

And all of this just leads into how are we helping our clients better manage their risk. So, we're also looking at some new opportunities on the clearing and the risk side, so we'll be seeing more of that rollout and it's just the speed and efficiency, which the cloud puts behind us is allowing that new product production that would otherwise had not seen specifically within the data business. Hope that helps.

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

Thanks, Julie. Simon, hopefully, that gave you some color on that.

[Simon Clinch, Analyst at Atlantic Equities]

That's pretty thorough. Yeah. Thank you very much.

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

Thanks, Simon.

[Operator]

Thank you. Next question comes from the line of Alex Kramm with UBS. Please proceed with your question.

[Alex Kramm, Analyst at UBS Research]

Yes. Hi. Good morning, everyone. Thanks for the proactive comments on some of the equity franchises, your DTE, and it's clearly some investors are comparing your trends versus some of your competitors out there. I guess, the other thing that stands out when I look at that franchise is that the Micro percentage has come really down a lot. I don't want to just simplify that as saying retail is off, but just wondering if you could comment on what's going on there. Do you see those volumes going elsewhere or is this when you talk to maybe your retail brokerage partners, is that just the drying up of retail activity post-COVID?

And then related to that, as you talk about the growth acceleration over the next decade or so, I mean, is retail still a component of that or was that just an interesting story opportunity over the last couple years, but now really it's about much bigger than other things again?

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

Alex, thank you. Appreciate your question. I'm going to let -- there's a lot of people kind of chomping at the bit to take that question, but I am going to let Tim start, and then I'm going to join in with rest of the team. Go ahead, Tim.

[Tim McCourt, Senior Managing Director, Global Head of Financial and OTC Products at CME Group]

Great. Thanks, Alex. Thanks for the question. When we look at the Micro E-mini complex at CME, certainly we've seen some mean reversion in volume, which is not surprising giving, as Terry mentioned, in his comments, the volatility coming inbound from the equity markets, as well as upward price trends in all of the major indices. When those things coupled together, it tends to be a less attractive trade to the more active individual client that we see that preferred the Micro over some other products available, not only in CME, but in the ecosystem more broadly.

But it's important to note this is Micro volumes coming off of a phenomenal record 2022. If we look at the Micro S&P 500 as an example, the Q2 volume that we've seen this quarter is well down, is still on par with what we saw in 2020 and 2021 and actually is higher than that. And the same holds true for the Micro NASDAQ. So, its a tough relative comp, but it's certainly a very strong product with respect to its risk management and trading needs that it provides.

The other thing that's interesting to note is the Micro launched in 2019, now a few years old, is really starting to mature as a product. And what I mean by that is, even though some of the volumes have come down, from a revenue perspective, it is actually flat to last year or slightly up through H1. And that's a result of two things. One, the pricing actions we've taken with respect to the Micro E-minis, which continues to be at a premium versus the other risk-adjusted regular E-minis, but the other is the member mix. So even in a lower volume environment, we're seeing larger non-member proportionality of that customer mix, which has increased the RPC about $0.10 since this time last year for Micro E-mini. So that is something that is important to remind people of is the revenue performance of Micro E-mini is different than the volume performance through H1 of 2023.

And with respect to maturation, the other point is, look at the open interest of Micro E-minis. If we look at the top 10 open interest days for the Micro E-mini complex at CME, all 10 are in June of 2023 with single-day open interest records in several of the Micro E-mini contracts. This is a statement that the Micro E-mini is becoming a risk management tool alongside our trading tool, where more and more clients are holding them versus just intraday trading, which is a very positive development for the overall health of the market.

The last point that I'll make on this is, we can't look at Micro E-minis in isolation. They go hand-in-hand with their older sibling the E-mini contract. And when you look at the combined performance and the resilience of the E-minis, the futures complex at CME for equity indices remains very strong to its most analogous product choice and that is the ETF. And what I mean by that, if we look at the S&P, we out-trade the top three S&P ETFs by a factor of 10.7 to 1. That is for Q2 of 2023, that is up from a factor of 9.4 one year ago in Q2 of 2022. Same thing for the NASDAQ. This quarter we out-trade the ETFs in our combined futures, 9.7 to 1 versus 7.3 in 2022. And similarly to the Dow, this quarter we out-traded the ETFs, 23.3 times, that is 16.2 times last year. So, despite the slowing growth in Micro E-minis off of a record year, we still a very strong equity futures offering here at CME.

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

Julie? Thanks, Tim.

[Julie Holzrichter, Chief Operating Officer at CME Group]

Yeah. And as Tim pointed out, certainly our equity portion of our retail business is the majority of that. But with equity vol hitting two-year lows, we would expect there to be some softness in the volume. However, our overall retail business remains extremely strong. We had a record-setting year last year and we're looking at just revenue being down slightly this year, which is very, very strong performance. We saw a positive growth in both Europe, greater LATAM, and also China in the second quarter.

And one of the real parameters that we often mentioned on this call and for us as a key sign of the health of this marketplace for retail participation is the total number of retail traders, which was up 7% in Q2-over-Q2 of 2022 and also just the number of new traders. So, our firm's ability and CME's ability to continue to attract new people to CME markets, that was also up 4% in Q2 of 2023. So, I think from our signs, we certainly see the equity vol had some impact on things, but the fact that we have a diverse asset class, we saw increased activity in some of the other asset classes by retail participants and still we're -- we're still very well-positioned for future growth quarters.

[Tim McCourt, Senior Managing Director, Global Head of Financial and OTC Products at CME Group]

And just to add a couple of data points to what Julie said, specifically, when you look at retail in our Metals complex, for example, retail volumes, year-to-date are up 21% and as you know, Metals is our highest rate per contract business at $1.50. Also, options growth has benefited from retail participation, up 8% this year. So, the benefit of being able to walk into a customer, any customer or distribution partner, and offering every major benchmark liquidity product to them means that when sector rotation happens, we're going to be the beneficiary of that. So we see strength in certain asset classes, when they start to rotate whether because you've got normalization of volatility or cost of capital, we're going to benefit from that and we see that that's the benefit of the story and the growth behind the franchise.

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

So, Alex, you've heard a few comments, and I think hopefully you find them all salient. And one of the things that we talk about retail and we always have is an ebb and flow situation for a lot of people. Our retail is described a little bit different as more professional type participants as Mr. Minclay [Phonetic] was pointing out.

So, when you talk about COVID and you talk about other factors, yes, that was in there, but our retail is classified as different than the average person trading on maybe a Robinhood platform or something of that nature. And what Tim had to say about how the competitors are performing against CME, you can clearly see that our volume share is not only not decreasing, but increasing against the look alike or competitive type products. So hopefully those questions have been answered properly for you.

[Alex Kramm, Analyst at UBS Research]

Yeah. Lots of great color. Thank you very much.

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

Thanks, Alex.

[Operator]

Thank you. Our next question comes from the line of Brian Bedell with Deutsche Bank. Please go ahead, sir.

[Brian Bedell, Analyst at Deutsche Bank Securities]

Great. Thanks. Good morning, folks. Thanks for taking my question. Maybe if I can just go back to the options story, obviously, that's been improving nicely, the numbers I'm looking at, I think options as a percentage of total ADV was in the mid-to-high teens over the last couple of years. Now, you've sort of vectored above 20%. So just wanted to sort of try to understand your confidence of that type of trend improving over the next year.

And then maybe just talk about the RPC dynamics of the Options business versus the futures in terms of whether you think that potentially accretive to RPC.

And you also mentioned on Page 3 of the quarterly earnings commentary about the direct front-end platform helping stimulate trading of electronic options. Is that just in the Energy complex or is that across the business?

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

Thanks, Brian. Derek and Tim, you want to start and then I'm going to say --

[Tim McCourt, Senior Managing Director, Global Head of Financial and OTC Products at CME Group]

Yeah, in reverse order. I'll actually start with your last question, Brian. So, yeah, you've heard us talk on previous calls about CME Direct, that is our proprietary front-end that we provide to our customers that gives them all the functionality, all the analytics, all the capabilities, and all the connectivity including API access to our markets for both futures and options that really started as a mechanism to make sure that we were able to provide the full breadth of capabilities and services to our global customer base seamlessly, connecting to everything that we have to offer. That's now extended itself. So, this is across asset class, not just limited to Energy, and the growth that we've seen there has been substantial. It's actually rapidly evolved to become the single largest ISV provider or link into our options business with the highest rates of penetration on the interest rate side. So, it's an integral part to our growth story.

In the options analytics space, we've developed a whole suite of capabilities, whether it's pre-trade analytics or post-trade tool to help customers look at that positions and strategy they want to implement, that's a new capability we've developed over the last four to five years and it's -- just as we continue to expand the tools and capabilities, it just brings more customers that are willing and able to trade options and creates a seamless experience, one single front-end into all of our asset classes with a full suite of functionality analytical tools. We think we're still in the early innings of developing those capabilities in partnership with QuikStrike and we're very happy with the growth that we're seeing there. That's actually becoming a critical part of our futures delivery, as well as all of our blocks are reported through there.

The last piece I'd note on the front-end there is that we're seeing the largest uptake in growth there is from some of our buy-side participants and brokers as well. So, this is a platform that brings customers to our market, provides a full suite of services and introduces them to everything we have to offer.

The last piece is the -- when you reference the overall percent of Options as a percent of total volume, there's two parts to that. Not only are we seeing Options continue to outpace futures, which is positive for the franchise in that more Options business brings more embedded futures hedging associated with it, but as I mentioned at the top of the call, with our Options business year-to-date, up about 24%, our non-US Options business is growing even faster, up 33% for the first full half year.

So, when we think about growth levers and opportunities, the way our sales force is out there, specifically educating clients on Options use how to access those tools at CME Group and the growth that we're seeing, we think we've got still a good deal of penetration yet ahead of us when you look at the footprint that we have in Options in Europe and Asia versus the US. So a lot to like in the story.

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

So, let me just accentuate a couple of points here, Brian, because I think it's really important. We are the largest futures exchange in the world. Our futures franchise is massive. One of the reasons it is what it is, is because of the growth of options. But the real growth is in the futures for the out-years. So if our options business continues to be here or better, it only bolsters our futures and hedging business going forward. That's to me a real story for the futures franchise of CME Group.

So, it's not just an options story like some people are talking about it or different firms they represent. We are a futures exchange with options and the options grow the futures as well. And that point cannot be missed. I don't want you to think we don't want to go in options and futures or not. So that's a very important point that we have to go forward.

[Brian Bedell, Analyst at Deutsche Bank Securities]

That's super-helpful. And just the RPC dynamics, I guess, of the options versus the futures.

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

Say that again.

[Brian Bedell, Analyst at Deutsche Bank Securities]

The RPC dynamics versus futures.

[Lynne Fitzpatrick, Chief Financial Officer at CME Group]

Yeah. So the total RPC this quarter across our Options complex was $0.666, slightly down from what we saw overall. It does depend on asset class, how that will compare and what it is trading in terms of those options.

[Brian Bedell, Analyst at Deutsche Bank Securities]

That's great color. Thank you so much.

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

Thanks, Brian.

[Operator]

Thank you. And up next we have a question from Craig Siegenthaler with Bank of America. Please go ahead, sir.

[Craig Siegenthaler, Analyst at Bank of America]

Hey, good morning, everyone. Our question is on pricing. Given your success with the larger-than-usual price hikes early this year, do we start to see larger price hikes again next year in 1Q '24 and then again in 1Q '25?

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

Hey, Craig. It's Terry Duffy. Let me make a comment on that. Price hikes are part of the business, but that's not the strategy and how we grow the business. So, we look -- everybody has got cost that they have -- are incurring and we're no different, but that's not our strategy to grow the revenue of the Company. Our strategy is to grow the business, not grow what we charge. So again, we will continue to look at that on a month-by-month basis and make decisions as we see it spread. But we're not prepared to say right now, what our pricing will or will not be in the next couple of years on the out-years.

Lynne?

[Lynne Fitzpatrick, Chief Financial Officer at CME Group]

And just to add to that, Craig, as you know, we do a very bottoms-up build on that pricing strategy. This is not an approach where we have a target that we are looking to hit, it is really market-by-market, product-by-product customer type, and we will determine what we think is the right adjustment, if any, for that market. So, it's something that we evaluate in that time period. We don't look at a multi-year pricing strategy. It really depends on the market environment, the health of the market. And what we ultimately are trying never to do is impact volumes, because we want to see that philosophy of trade moving through our systems given the high level of incremental margins that we earn on that trading.

[Craig Siegenthaler, Analyst at Bank of America]

Thank you.

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

Thanks, Craig.

[Operator]

Thank you. And our next question comes from the line of Owen Lau with Oppenheimer. Please proceed with your question.

[Owen Lau, Analyst at Oppenheimer]

Hey, good morning. Thank you for taking my questions. So I have a quick two-part question. The first one is a follow-up to the market data question. It was up year-over-year, but down sequentially. How much was the one-time payment in the first quarter?

And then the second one is about digital assets. I think CME will launch Ether, Bitcoin ratio futures soon. Could you please give us an update on the digital assets trading and institutional participation in CME and how could the summary judgment from Judge Torres on the Ripple case potentially impact CME? Thanks.

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

So, thanks, Owen. I'm going to ask Lynne to give you the first one on the market data question and Tim will touch on the digital assets.

[Lynne Fitzpatrick, Chief Financial Officer at CME Group]

Yeah. So, Owen, in the first quarter, we saw about $4 million in one-time audit fee and catch-up payments that we didn't see in Q2. This quarter we saw about $0.5 million in audit fees. So that really explains that differential Q1 to Q2.

[Tim McCourt, Senior Managing Director, Global Head of Financial and OTC Products at CME Group]

Great. Thanks, Owen. When we look at the cryptocurrency complex at CME, you're correct, we recently announced, which I think is an innovative and interesting product and that is the Bitcoin Ether ratio spread contract that will go live the weekend of July 29th, that's interesting where it's the effectively the price of Ether divided by the price of Bitcoin in one contract that will trade alongside the other cryptocurrency products including offsets for clearing at CME.

When we look at the crypto complex at CME, it remains strong, our value proposition remains salient with our institutional client base. We've seen continued adoption of our products in terms of both traders in the OTC space, as well as futures traders, as well as the growing importance of our contracts as the underlying as some of the most popular ETFs out there in this space, which are continuing to grow both trading volume and open interest.

When we look at the volume that we're doing in the larger-sized Bitcoin Ether contracts that is up about 6% versus this period H1 through 2022 and on pace for another strong year in crypto here at CME. When we look at our product development, we do stay currently in the Bitcoin and Ether lane for tradable products. We do have a multitude of reference rates.

But with regards to your question about the Ripple case, it's really not in our position to comment on that case. Our mantra and the philosophy that we use is we will continue to only deploy product as the regulated venue offering regulated products and we will wait for further regulatory clarity from the SEC and the CFTC before we introduce additional products.

[Adam Minick, Senior Director, Investor Relations at CME Group]

Thanks, Tim. Thank you, Owen.

[Owen Lau, Analyst at Oppenheimer]

Thanks.

[Operator]

Thank you. And our next question comes from the line of Ken Worthington with J.P. Morgan. Please go ahead.

[Kenneth Worthington, Analyst at J.P. Morgan]

Hi. Good morning and thanks for taking the question. The SEC has a number of proposals for centralized clearing in the rates markets for treasuries and repo. So a couple of questions here. I guess, first, Terry, which are the major parts of the clearing proposals are most likely to make their way into the final rules? Maybe second, how do you think these rules could impact rate liquidity and volatility, and ultimately flow through CME rate activity? And then lastly, to what extent is participating directly in a clearing platform for treasuries and repo important or even a priority for CME?

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

Okay, Ken, there's a lot to unpack there and a lot that I don't have the answers for, because these proposals that you're referring to at the SEC and the Treasury market, I think there's a lot to be done yet before they are finalized to a point where we see how they're going to be implemented.

As far as the trading on the repo, Tim, if you want to comment on that. But on the SEC proposals, Ken, I don't see anything in there that's a negative for CME for starters, I'll make sure I said that, if in fact it was to go as proposed, and I see it only as a net positive for CME. So, what that is, I don't want to make predictions on what it could or could not be. It reminds me a lot of and I don't want to put the same analysis on it, but during 2010, Dodd-Frank, one day said that swaps clearing was going to be worth $1 billion so everybody that had clearing house was a bit of a misdirect, because that was made-up by some government officials, not us. So, I want to be careful on that, ken, about how we make any predictions, where it's going, but I will say that I don't see any negatives in any of the proposals for CME as I've gone through them.

Tim, you want to make a comment there?

[Tim McCourt, Senior Managing Director, Global Head of Financial and OTC Products at CME Group]

Sure. I think the one thing I would add is, while we continue to evaluate the proposals and the various suggestions and regulatory reforms that may be discussed, we're certainly looking to participate in those conversations with our clients and with the regulators to see what makes sense from a risk management and a clearing perspective for our customers.

As Terry said, very hard to predict what the final rules may look like. But, I think, broadly speaking, when we look at the totality and the gravity of the interest rate complex, CME across futures and options, cash market and BrokerTec and OTC clearing, we certainly are already in a position of strength with the ability to unlock capital efficiencies for our clients, we're averaging about $7.5 billion of savings across the portfolio margin in the rates complex today. So anything that would increase the velocity or the benefits of central clearing certainly will be something that we're looking to engage.

But it's important to note, not only with our portfolio margin, because as Terry said earlier with thick cross-margining on the horizon with the expanded suite of products available to the clients across SOFR, the Ultra 10 Notes, the Ultra 10 bonds is that we're already providing a lot of capital savings to clients, where these may be additive, but we'll have to wait and see how the final rules shake out.

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

Thanks, Tim. Thanks, Ken.

[Kenneth Worthington, Analyst at J.P. Morgan]

Great. Thank you.

[Operator]

Thank you. And up next we have a question from the line of Michael Cyprys with Morgan Stanley. Please proceed with your question.

[Michael Cyprys, Analyst at Morgan Stanley]

Hey, good morning. Thanks for taking the question. Wanted to ask about capital management. If we look back over the past decade, you guys have returned a tremendous amount of capital through the dividend and primarily the special dividend; a lot of that was during a zero-rate backdrop, but with meaningfully higher rates today over 5%. Just curious how the rate backdrop is impacting your calculus and thought process around capital management and to what extent might you think about evolving shifting the policy and considering buybacks? Thank you.

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

Thanks, Mike. I'll let Lynne comment, then I will as well.

[Lynne Fitzpatrick, Chief Financial Officer at CME Group]

Yeah. So as you know, Michael, we've had that policy in place with our variable dividend. Since 2012, we've returned over $21.5 billion to shareholders in the form of dividends during that time. We do think a lot of our shareholders appreciate the transparency of that approach and the ability to track progress for that as we move through the year. So, we do like both the flexibility and that transparency. That being said, we always do look at alternatives to make sure that the way we are returning capital is the most attractive form for our investor base. And to-date, we have found that that dividend policy has been preferred.

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

And Michael, just so you know, I mean, as far as share repurchases, we've talked about that, we continue to talk about it; and as Lynne just referenced, we will do what we believe is in the best interest of the shareholders at that time. So, we're not taking anything off the table, but right now, our dividend policy has proven out to be the right one for now.

[Michael Cyprys, Analyst at Morgan Stanley]

Great. Thank you.

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

Thank you.

[Operator]

Thank you. Our next question comes from the line of Patrick Moley with Piper Sandler. Please go ahead, sir.

[Patrick Moley, Analyst at Piper Sandler Companies]

Yeah. Good morning. Thanks for taking my question. So, I wanted to go back to the expanded cross-margining opportunities with the DTCC. Terry, I know this is something that's been in the works for a little while now. So just wondering what maybe caused us to come to fruition now? And then assuming you do receive regulatory approval and launch in the first quarter, how quickly would you expect that to maybe ramp in terms of client utilization? Thanks.

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

Yeah. Thanks, Patrick, and congratulations on your new role there at the firm. I will say a couple of things. The agreement with DTCC has been in the works for a long time. So you're exactly right. A little frustrating, and why now, I think that when you look at where -- listen, we're only one part of the equation, we need DTCC to be prepared to do this as well. They had some other projects in the works they had to finish up and everything takes a little bit longer than you anticipate. So, we couldn't control their side of what they needed to do for this agreement.

We have now come to a finalization on this with them. And like I said, earlier, we're looking to have this as soon as it's approved hopefully being implemented by Q1 of next year. And again, extremely excited about what this could do for the marketplace, because of what Tim and others have said, what we see on the out-years as far as risk management goes, and how necessary its going to be for all products. So, if you're going to have that capital efficiencies amongst products is key in order to grow these businesses and make it more efficient for each and every client. So, we do believe that this cross-margining agreement will be extremely beneficial to the clients and make their capital more efficient, which in return should benefit CME immensely.

Tim, I'll let you comment more on the agreement under what Patrick has raised.

[Tim McCourt, Senior Managing Director, Global Head of Financial and OTC Products at CME Group]

Yeah. Thanks, Terry. So, again, when we look at this announcement, we're excited, one that we're finally able to bring this to market early next year, but it's also sort of when we look at the benefit to clients, when we look at the immediate benefits or the near-term benefit, it's certainly expansions of the products that are now available for the cross-margin agreement, as we're saying earlier included our SOFR futures, the Ultra 10-year US Treasury note futures, the Ultra Treasury bond futures, the six-year Treasury notes and bonds and repo transactions that have a time to maturity of greater than one year will also be eligible.

This is exciting in terms of trying to unlock those benefits as we've said previously on the earnings calls and certainly before we think our present clients are taking advantage of them. But typically more in the order of 20% or 30%, we do you expect to get those offset percentages closer to 70% or slightly higher, but this is the first step, right? The part of -- important part of entering into these agreements, is that we will continue to work with the client to try and avail even more capital efficiencies after this initial rollout, this is something that we're engaging with clients about and we look to further expand the programs to allow clients to avail these efficiencies, in addition to the common member proprietary account. So lots of things on the horizon that would continue to explore years down the road beyond just the initial rollout of early next year.

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

Thanks, Tim. Thanks, Patrick.

[Patrick Moley, Analyst at Piper Sandler Companies]

Very helpful. Yeah. Thank you.

[Operator]

Thank you. And we now have a question from the line of Chris Allen with Citi. Please go ahead, sir.

[Christopher Allen, Analyst at Smith Barney Citigroup]

Yeah. Good morning, everyone. I was wondering if you can give an update on the collateral balances, both cash and non-cash during the quarter, related revenues that generated during the quarter and where they currently stand for July?

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

Thanks, Chris. Lynne?

[Lynne Fitzpatrick, Chief Financial Officer at CME Group]

Sure. If we look at the quarter, the average balance for cash was $120.1 billion. That was up from $109.6 billion last quarter. For the non-cash balances, we saw $109.4 billion on average, up from $99.2 billion in the first quarter. So, we earned $107 million on the cash balances this quarter and just under $20 million on the non-cash balances this quarter. Again, that non-cash amount rolls through the other revenue line. If you look at year-to-date -- month-to-date so far in July, the balances in cash have come down. We're seeing about a $100.9 billion in cash on average so far in July. And the non-cash balances so far this month are running at $127.9 billion.

[Christopher Allen, Analyst at Smith Barney Citigroup]

Great. Thanks.

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

Thanks, Chris. Thank you. And we now have a question from the line of Andrew Bond with Rosenblatt Securities. Please go ahead.

[Andrew Bond, Analyst at Rosenblatt Securities]

Hi. Thanks. Good morning. So, Energy open interest is beginning to trend upward from other longer-term decline. Can you talk a little bit about the overall health of the Energy business, the drivers here, structurally and if the geopolitical environment is still impacting current trends in natural gas and oil? Thanks.

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

Thanks, Andrew. Good question. And Derek?

[Derek Sammann, Senior Managing Director, Global Head of Commodities, Options & International Markets at CME Group]

Yeah. It's -- I think we've seen a really nice return to, I would say, normalized levels of volatility, and therefore, normalized levels of margin required to trade, as we saw some of that business shift out, particularly financial players step out of the Energy business last year, and we're seeing that business returns significantly. You pointed to the trend not just in the open interest, but volumes as well.

When you look at the primary drivers, there are some cyclical some structural. The cyclicals where we certainly put ourselves in the position to be the biggest beneficiaries of those and you look at, particularly the strength of a globalizing natural gas franchise that is really globally centered around Henry Hub, natural gas continues to be exported at record amounts out of the US through the LNG facilities, that's at max capacity right now, they're more facilities coming onboard over the next five years. So from a TOM perspective, CME Group's Henry Hub franchise is the central pricing point for global natural gas.

When you look at growth across the client segments there, we're seeing significant growth, and actually, new client acquisition is happening the fastest in natural gas with our European customer base. That shouldn't surprise, given some of the challenges that Ukraine war has posed in terms of disruption to fuel supplies above crude and natural gas. So, when we look at that global growth as particularly strong in natural gas out of Europe and we're seeing significant growth in options there as well.

So, similar structural story that's taking place in crude oil. As you know, in June, Platts implemented a Midland WTI marker into the Brent basket and that has actually just further reinforced WTI as the primary global benchmark setting the price of oil in terms of the outsize footprint WTI has in the pricing of oil. Seeing the shift, and as I talked about on the last call that over time WTI would be that global physical benchmark of reference that position has only strengthened, and we have taken significant work to build out, as I mentioned before, the Gulf Coast crude grades contracts that connects specifically our physically delivered WTI contract out to the export market as the US is now exporting over 4 million barrels a day, a record clip as well.

So those contracts themselves have over 500,000 open interest, that complements the growth to just under 2 million contracts open interest in WTI. So, the structural shifts for both Henry Hub, a market that we own 82% market share of and WTI market we own 90% market share of, will continue to be central to not just the energy transition, but growth in the franchise overall across client segments.

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

Andrew, let me just say one more thing, as you referenced it and I talk about this a lot too is geopolitical. I think geopolitical has got a factor in every single trade and every single asset class going forward. I mean, the tensions around the world are just amazing when you look at not only with the -- what's going on between Ukraine and Russia and the rest of the world being involved in it, the potential of what's going on between China and Taiwan. I mean, the tensions are so high all over the world, the geopolitical has a factor in every one of these markets and risk management is critical to us. So, I think you're spot-on for raising the geopolitical risk, but it's not only associated with LNG, it is across the board.

[Andrew Bond, Analyst at Rosenblatt Securities]

Thanks, Derek and Terry.

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

Thanks, Andrew.

[Operator]

Thank you. And our final question comes from the line of Brian Bedell with Deutsche Bank. Please proceed with your question.

[Brian Bedell, Analyst at Deutsche Bank Securities]

Great. My questions have been answered. Just one clarification. The rate paid -- or I'm sorry, the rate earned on the cash collateral balances in the second quarter and the rate that you're paying out to the clients?

[Lynne Fitzpatrick, Chief Financial Officer at CME Group]

Yeah. So the rate on the Fed account remains at the 25 basis points. It's been at that level for the last eight rate hikes. We are earning -- we earned in the second quarter about 34 basis points, up just slightly from what we had seen in Q1.

[Brian Bedell, Analyst at Deutsche Bank Securities]

Okay. Great. Thank you.

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

Thanks, Brian.

[Operator]

Thank you. I will now turn the call back to the management for their closing remarks. Please go ahead.

[Terrence A. Duffy, Chairman and Chief Executive Officer at CME Group]

Let me thank all of you for participating in the call today. We appreciate your questions and the opportunity to answer them. Have a nice day and we look forward to speaking to you soon. Thank you.

[Operator]

[Operator Closing Remarks]

Participants

Corporate Executives

• Adam Minick, Senior Director, Investor Relations
• Terrence A. Duffy, Chairman and Chief Executive Officer
• Lynne Fitzpatrick, Chief Financial Officer
• Tim McCourt, Senior Managing Director, Global Head of Financial and OTC Products
• Derek Sammann, Senior Managing Director, Global Head of Commodities, Options & International Markets
• Julie Holzrichter, Chief Operating Officer
• Sunil Cutinho, Chief Information Officer

Analysts

• Benjamin Budish, Barclays PLC
• Dan Fannon, Jefferies & Company
• Kyle Voigt, Keefe, Bruyette & Woods
• Simon Clinch, Atlantic Equities
• Alex Kramm, UBS Research
• Brian Bedell, Deutsche Bank Securities
• Craig Siegenthaler, Bank of America Co.
• Owen Lau, Oppenheimer Holdings Inc.
• Kenneth Worthington, J.P. Morgan
• Michael Cyprys, Morgan Stanley
• Patrick Moley, Piper Sandler Companies
• Christopher Allen, Smith Barney Citigroup
• Andrew Bond, Rosenblatt Securities